Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome

Frank González, Neal S. Rote, Judi Minium, Amy L. Weaver, John P. Kirwan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Women with polycystic ovary syndrome (PCOS) have chronic low level inflammation which can increase the risk of atherogenesis. We evaluated the status of circulating macrophage migration inhibitory factor (MIF), a proinflammatory cytokine involved in atherogenesis, in women with PCOS and weight-matched controls. Two-way analysis of variance models adjusted for age were fit to evaluate the effect of PCOS status (PCOS vs. controls) and weight-class (obese vs. lean) on MIF and other parameters. MIF levels were significantly (p<0.001) higher in women with PCOS (lean: 37.7±10.6ng/ml; obese: 54.6±15.2ng/ml) compared to controls (lean: 4.8±0.6ng/ml; obese: 17.5±8.0ng/ml) regardless of weight-class. CRP levels were significantly (p<0.001) higher in obese subjects (PCOS: 6.2±1.9mg/l; controls: 6.7±1.4mg/l) compared to lean subjects (PCOS: 0.9±0.4mg/l; controls: 0.2±01mg/l) after controlling for PCOS status. MIF levels directly correlated with % truncal fat (r=0.41, p<0.05), and plasma levels of CRP (r=0.42, p=0.05), LH (r=0.45, p=0.04), testosterone (r=0.53, p<0.008), androstendione (r=0.58, p<0.005). ISOGTT inversely correlated with plasma levels of MIF (r=-0.51, p<0.02) and CRP (r=-0.73, p<0.001). Circulating MIF is elevated in PCOS independent of obesity, but both PCOS and obesity contribute to a proatherogenic state. In PCOS, abdominal adiposity and hyperandrogenism may exacerbate the risk of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)240-244
Number of pages5
JournalCytokine
Volume51
Issue number3
DOIs
StatePublished - Sep 1 2010

Fingerprint

Macrophage Migration-Inhibitory Factors
Polycystic Ovary Syndrome
Plasmas
Atherosclerosis
Analysis of variance (ANOVA)
Weights and Measures
Testosterone
Fats
Obesity
Cytokines
Hyperandrogenism
Adiposity
Analysis of Variance

Keywords

  • Abdominal adiposity
  • Androgens
  • Atherosclerosis
  • Inflammation
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology

Cite this

González, F., Rote, N. S., Minium, J., Weaver, A. L., & Kirwan, J. P. (2010). Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. Cytokine, 51(3), 240-244. https://doi.org/10.1016/j.cyto.2010.06.008

Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. / González, Frank; Rote, Neal S.; Minium, Judi; Weaver, Amy L.; Kirwan, John P.

In: Cytokine, Vol. 51, No. 3, 01.09.2010, p. 240-244.

Research output: Contribution to journalArticle

González, F, Rote, NS, Minium, J, Weaver, AL & Kirwan, JP 2010, 'Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome', Cytokine, vol. 51, no. 3, pp. 240-244. https://doi.org/10.1016/j.cyto.2010.06.008
González, Frank ; Rote, Neal S. ; Minium, Judi ; Weaver, Amy L. ; Kirwan, John P. / Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. In: Cytokine. 2010 ; Vol. 51, No. 3. pp. 240-244.
@article{686ec21692fb40759d0248526036eb94,
title = "Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome",
abstract = "Women with polycystic ovary syndrome (PCOS) have chronic low level inflammation which can increase the risk of atherogenesis. We evaluated the status of circulating macrophage migration inhibitory factor (MIF), a proinflammatory cytokine involved in atherogenesis, in women with PCOS and weight-matched controls. Two-way analysis of variance models adjusted for age were fit to evaluate the effect of PCOS status (PCOS vs. controls) and weight-class (obese vs. lean) on MIF and other parameters. MIF levels were significantly (p<0.001) higher in women with PCOS (lean: 37.7±10.6ng/ml; obese: 54.6±15.2ng/ml) compared to controls (lean: 4.8±0.6ng/ml; obese: 17.5±8.0ng/ml) regardless of weight-class. CRP levels were significantly (p<0.001) higher in obese subjects (PCOS: 6.2±1.9mg/l; controls: 6.7±1.4mg/l) compared to lean subjects (PCOS: 0.9±0.4mg/l; controls: 0.2±01mg/l) after controlling for PCOS status. MIF levels directly correlated with {\%} truncal fat (r=0.41, p<0.05), and plasma levels of CRP (r=0.42, p=0.05), LH (r=0.45, p=0.04), testosterone (r=0.53, p<0.008), androstendione (r=0.58, p<0.005). ISOGTT inversely correlated with plasma levels of MIF (r=-0.51, p<0.02) and CRP (r=-0.73, p<0.001). Circulating MIF is elevated in PCOS independent of obesity, but both PCOS and obesity contribute to a proatherogenic state. In PCOS, abdominal adiposity and hyperandrogenism may exacerbate the risk of atherosclerosis.",
keywords = "Abdominal adiposity, Androgens, Atherosclerosis, Inflammation, Polycystic ovary syndrome",
author = "Frank Gonz{\'a}lez and Rote, {Neal S.} and Judi Minium and Weaver, {Amy L.} and Kirwan, {John P.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.cyto.2010.06.008",
language = "English (US)",
volume = "51",
pages = "240--244",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome

AU - González, Frank

AU - Rote, Neal S.

AU - Minium, Judi

AU - Weaver, Amy L.

AU - Kirwan, John P.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Women with polycystic ovary syndrome (PCOS) have chronic low level inflammation which can increase the risk of atherogenesis. We evaluated the status of circulating macrophage migration inhibitory factor (MIF), a proinflammatory cytokine involved in atherogenesis, in women with PCOS and weight-matched controls. Two-way analysis of variance models adjusted for age were fit to evaluate the effect of PCOS status (PCOS vs. controls) and weight-class (obese vs. lean) on MIF and other parameters. MIF levels were significantly (p<0.001) higher in women with PCOS (lean: 37.7±10.6ng/ml; obese: 54.6±15.2ng/ml) compared to controls (lean: 4.8±0.6ng/ml; obese: 17.5±8.0ng/ml) regardless of weight-class. CRP levels were significantly (p<0.001) higher in obese subjects (PCOS: 6.2±1.9mg/l; controls: 6.7±1.4mg/l) compared to lean subjects (PCOS: 0.9±0.4mg/l; controls: 0.2±01mg/l) after controlling for PCOS status. MIF levels directly correlated with % truncal fat (r=0.41, p<0.05), and plasma levels of CRP (r=0.42, p=0.05), LH (r=0.45, p=0.04), testosterone (r=0.53, p<0.008), androstendione (r=0.58, p<0.005). ISOGTT inversely correlated with plasma levels of MIF (r=-0.51, p<0.02) and CRP (r=-0.73, p<0.001). Circulating MIF is elevated in PCOS independent of obesity, but both PCOS and obesity contribute to a proatherogenic state. In PCOS, abdominal adiposity and hyperandrogenism may exacerbate the risk of atherosclerosis.

AB - Women with polycystic ovary syndrome (PCOS) have chronic low level inflammation which can increase the risk of atherogenesis. We evaluated the status of circulating macrophage migration inhibitory factor (MIF), a proinflammatory cytokine involved in atherogenesis, in women with PCOS and weight-matched controls. Two-way analysis of variance models adjusted for age were fit to evaluate the effect of PCOS status (PCOS vs. controls) and weight-class (obese vs. lean) on MIF and other parameters. MIF levels were significantly (p<0.001) higher in women with PCOS (lean: 37.7±10.6ng/ml; obese: 54.6±15.2ng/ml) compared to controls (lean: 4.8±0.6ng/ml; obese: 17.5±8.0ng/ml) regardless of weight-class. CRP levels were significantly (p<0.001) higher in obese subjects (PCOS: 6.2±1.9mg/l; controls: 6.7±1.4mg/l) compared to lean subjects (PCOS: 0.9±0.4mg/l; controls: 0.2±01mg/l) after controlling for PCOS status. MIF levels directly correlated with % truncal fat (r=0.41, p<0.05), and plasma levels of CRP (r=0.42, p=0.05), LH (r=0.45, p=0.04), testosterone (r=0.53, p<0.008), androstendione (r=0.58, p<0.005). ISOGTT inversely correlated with plasma levels of MIF (r=-0.51, p<0.02) and CRP (r=-0.73, p<0.001). Circulating MIF is elevated in PCOS independent of obesity, but both PCOS and obesity contribute to a proatherogenic state. In PCOS, abdominal adiposity and hyperandrogenism may exacerbate the risk of atherosclerosis.

KW - Abdominal adiposity

KW - Androgens

KW - Atherosclerosis

KW - Inflammation

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=77955276494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955276494&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2010.06.008

DO - 10.1016/j.cyto.2010.06.008

M3 - Article

C2 - 20598902

AN - SCOPUS:77955276494

VL - 51

SP - 240

EP - 244

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 3

ER -